Physician profile
Mark N Hendrixson
NPI 1457469223
$11,635.43
in general payments reported to CMS, 2019-2025
77 companies · $2,157 in 2025
The $2,157 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,317 · 2020: $610 · 2021: $1,063 · 2022: $1,992 · 2023: $2,153 · 2024: $2,343 · 2025: $2,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,541 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,541.24 |
| Education | $111.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,274.75 | 2019-2025 | Calquence, Tagrisso, Enhertu |
| Novartis Pharmaceuticals Corporation | $1,144.81 | 2019-2025 | |
| Janssen Biotech, INC. | $660.87 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| E.R. Squibb & Sons, L.L.C. | $621.68 | 2019-2025 | Opdivo, Krazati, Pomalyst |
| Daiichi Sankyo INC. | $482.82 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $469.39 | 2019-2025 | Alunbrig, Ninlaro, Iclusig |
| Merck Sharp & Dohme LLC | $388.35 | 2019-2025 | Keytruda, Lynparza, Reblozyl |
| Pfizer INC. | $360.83 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $339.80 | 2019-2025 | |
| Celgene Corporation | $308.15 | 2019-2025 | Reblozyl, Pomalyst |
| Lilly USA, LLC | $295.51 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Genzyme Corporation | $287.72 | 2021-2025 | |
| Amgen INC. | $278.57 | 2019-2023 | Kyprolis, Vectibix, Xgeva |
| Pharmacyclics LLC, An Abbvie Company | $270.34 | 2019-2023 | Imbruvica |
| Eisai INC. | $257.63 | 2019-2025 |
Show all 77 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $247.68 | 2020-2025 | Jakafi, Monjuvi, Zynyz |
| Glaxosmithkline, LLC. | $231.46 | 2020-2025 | Ojjaara, Jemperli |
| Regeneron Healthcare Solutions, INC. | $208.76 | 2019-2025 | Libtayo |
| Exelixis INC. | $190.89 | 2019-2025 | Cabometyx |
| Seagen INC. | $168.78 | 2020-2025 | Tukysa |
| Adaptive Biotechnologies Corporation | $160.02 | 2022-2025 | Clonoseq |
| Abbvie INC. | $150.50 | 2022-2025 | |
| Rigel Pharmaceuticals, INC. | $148.55 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Tersera Therapeutics LLC | $147.82 | 2022-2025 | Zoladex, Quzyttir |
| Emd Serono, INC. | $135.57 | 2019-2025 | |
| Astellas Pharma US INC | $133.07 | 2022-2025 | Padcev, Xospata, Vyloy |
| Mirati Therapeutics, INC. | $131.73 | 2023-2024 | Krazati |
| Aveo Pharmaceuticals, INC. | $128.11 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $119.69 | 2021-2025 | Onivyde |
| Jazz Pharmaceuticals INC. | $99.05 | 2020-2024 | |
| Pharmacosmos Therapeutics INC. | $98.80 | 2020-2025 | Monoferric |
| Taiho Oncology, INC. | $94.67 | 2019-2025 | |
| Pharmaessentia USA Corporation | $88.77 | 2023-2025 | Besremi |
| Karyopharm Therapeutics INC. | $87.89 | 2022-2025 | Xpovio |
| Kyowa Kirin, INC. | $81.74 | 2021-2025 | Poteligeo |
| Genentech USA, INC. | $80.09 | 2019-2025 | Venclexta |
| Eusa Pharma (US) LLC | $76.82 | 2019-2022 | |
| Genmab U.S., INC. | $73.86 | 2023-2025 | Epkinly |
| Beone Medicines USA, INC. | $72.07 | 2025 | Tevimbra, Brukinsa |
| Array Biopharma INC | $71.39 | 2022-2025 | Lorbrena, Mektovi, Braftovi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.27 | 2019-2024 | Gilotrif |
| Gilead Sciences, INC. | $56.33 | 2019-2022 | |
| Servier Pharmaceuticals LLC | $53.01 | 2024-2025 | |
| Legend Biotech USA INC. | $49.19 | 2024-2025 | Carvykti |
| Sobi, INC | $48.08 | 2022-2024 | |
| Beigene USA, INC. | $41.62 | 2024-2025 | Tevimbra, Brukinsa |
| Amag Pharmaceuticals, INC. | $37.77 | 2019 | |
| Spectrum Pharmaceuticals INC. | $34.51 | 2024-2025 | Rolvedon |
| Alexion Pharmaceuticals, INC. | $34.41 | 2019-2024 | Ultomiris |
| Tesaro, INC. | $33.70 | 2019 | |
| Geron Corporation | $33.38 | 2025 | Rytelo |
| Agios Pharmaceuticals, INC. | $30.34 | 2025 | Pyrukynd |
| Tempus Ai, INC | $28.85 | 2024 | Xt Cdx |
| Dova Pharmaceuticals | $26.71 | 2019-2020 | |
| Celltrion USA INC. | $25.79 | 2025 | Vegzelma |
| Accord Healthcare, INC. | $23.07 | 2025 | |
| Puma Biotechnology, INC. | $21.88 | 2019 | |
| Cycle Pharmaceuticals INC | $21.65 | 2025 | Phyrago |
| Deciphera Pharmaceuticals INC. | $19.59 | 2022 | |
| Sun Pharmaceutical Industries INC. | $19.05 | 2024 | |
| Acceleron Pharma, INC. | $18.32 | 2021 | |
| Acrotech Biopharma INC. | $18.29 | 2025 | Beleodaq |
| G1 Therapeutics, INC. | $18.10 | 2022 | |
| Amneal Pharmaceuticals LLC | $18.04 | 2024 | Neulasta |
| Clovis Oncology, INC. | $17.48 | 2020 | |
| Novocure INC. | $17.48 | 2024 | Optune Lua (Novottf-200t) |
| Recordati_rare_diseases_inc. | $17.09 | 2025 | Enjaymo |
| Blue Earth Diagnostics | $17.05 | 2021 | |
| Sumitomo Pharma America, INC. | $16.93 | 2023 | Orgovyx |
| Advanced Accelerator Applications | $15.80 | 2020 | |
| Coherus Oncology, INC. | $15.56 | 2021 | |
| Kite Pharma, INC. | $14.75 | 2020 | |
| Apellis Pharmaceuticals, INC. | $14.48 | 2024 | Empaveli |
| Mylan Institutional INC. | $14.00 | 2023 | Fulphila |
| Verity Pharmaceuticals INC. | $13.80 | 2023 | Trelstar |
| Organon LLC | $13.17 | 2021 | |
| Janssen Pharmaceuticals, INC | $2.89 | 2019 |
Drugs and devices associated with these payments
Enhertu $419Opdivo $274Imbruvica $257Kisqali $198Calquence $191Lenvima $181Krazati $180Keytruda $170Tukysa $168Tecvayli $167Verzenio $158Jaypirca $158Nubeqa $148Reblozyl $144Epkinly $140Libtayo $139Ibrance $136Retevmo $136Darzalex $135Clonoseq $132Tagrisso $127Pomalyst $126Xofigo $116Talvey $110Scemblix $108Alunbrig $104Ojjaara $103Sarclisa $89.52Besremi $88.77Stivarga $86.75Vitrakvi $86.75Zoladex $83.00Onivyde $81.80Jakafi $80.87Lynparza $80.06Tevimbra $75.86Xpovio $73.11Padcev $70.30Lutathera $66.38Venclexta $66.31Enjaymo $62.55Ninlaro $62.39Mekinist $58.65Fotivda $57.08Lonsurf $56.36Inqovi $56.36Braftovi $54.19Lorbrena $54.19Mektovi $54.19Zepzelca $54.11Rezlidhia $53.53Tavalisse $53.53Tibsovo $53.01Akeega $51.51Balversa $51.51Erleada $51.51Carvykti $50.86Elrexfio $44.13Adcetris $44.13Rybrevant $43.25Xospata $41.64Poteligeo $39.91Injectafer $39.87Orgovyx $39.26Cabometyx $37.99Brukinsa $37.83Monoferric $36.65Rolvedon $34.51Xalkori $34.11Imfinzi $33.91Rytelo $33.38Pluvicto $30.80Pyrukynd $30.34Zynyz $28.99Monjuvi $28.99Xt Cdx $28.85Gavreto $28.53Promacta $28.38Quzyttir $27.39Vegzelma $25.79Opdualag $24.78Vyloy $24.76Fabhalta $24.72Wayrilz $24.19Vonjo $24.02Camcevi $23.07Xtandi $22.33Talzenna $22.33Iclusig $22.23Inlyta $22.16Jemperli $22.14Phyrago $21.65Vpriv $21.40Bosulif $21.21Datroway $20.43Ultomiris $19.98Yonsa $19.05Odomzo $19.05Gilotrif $18.94Beleodaq $18.29
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hendrixson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.